Lv4
772 积分 2025-07-07 加入
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
17小时前
待确认
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)
17小时前
待确认
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
17小时前
待确认
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
17小时前
待确认
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
18小时前
待确认
Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
2天前
求助中
CLL-563: Bexobrutideg (NX-5948), a Novel Bruton's Tyrosine Kinase Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Findings from an Ongoing Phase 1a Study
4天前
求助中
Efficacy/Safety of the BTK Degrader NX-5948 in Waldenström macroglobulinemia: An Ongoing Phase 1a/b Study
4天前
已完结
Microglial diversity in neuropathic pain
4天前
已完结
Bruton Tyrosine Kinase Degraders
4天前
已完结
皖公网安备34019202002308
